AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9876753 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic metoclopramide in females
Number of subjects: 85
Study 8541815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol, 150 mg.day‐1
Number of subjects: 20
Study 8541815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8541815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 20
Study 2121104 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg of recombinant human IFN‐gamma
Number of subjects: 8
Study 2121104 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg of recombinant human IFN‐gamma
Number of subjects: 8
Study 2121104 — intervention group
Group type: COMPARATOR
Intervention: Diluent alone (control)
Number of subjects: 8
Study 750151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of hyperosmotic solutions made with glycerol
Number of subjects: 0
Study 750151 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with coeliac disease
Number of subjects: 0
Study 7083658 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (excision arthroplasty of the forefoot)
Number of subjects: 65
Study 7083658 — intervention group
Group type: COMPARATOR
Intervention: Non-operative management
Number of subjects: 65
Study 31264085 — intervention group
Group type: EXPERIMENTAL
Intervention: Biophysical therapy (electromagnetic information transfer through aqueous system procedure every 3 months)
Number of subjects: 238
Study 31264085 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment with renin‐angiotensin‐aldosterone system inhibitors)
Number of subjects: 238
Study 29405515 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-PSN therapy (intradermal injections, twice weekly for three weeks)
Number of subjects: 24
Study 26332798 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% caloric restriction (CR group, n = 143)
Number of subjects: 218
Study 24796339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1010
Study 24796339 — intervention group
Group type: EXPERIMENTAL
Intervention: Delcasertib 50 mg/h
Number of subjects: 1010
Study 24796339 — intervention group
Group type: EXPERIMENTAL
Intervention: Delcasertib 150 mg/h
Number of subjects: 1010
Study 24796339 — intervention group
Group type: EXPERIMENTAL
Intervention: Delcasertib 450 mg/h
Number of subjects: 1010
Study 21959687 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D navigation (Group II)
Number of subjects: 200
Study 21959687 — intervention group
Group type: COMPARATOR
Intervention: Standard navigation (Group I)
Number of subjects: 200
Study 21959687 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 19849677 — intervention group
Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip tracheal tube
Number of subjects: 102
Study 19849677 — intervention group
Group type: COMPARATOR
Intervention: Conventional tip tracheal tube
Number of subjects: 102
Study 17663098 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp-acupuncture plus body-acupuncture combined with body therapy and performance therapy
Number of subjects: 80
Study 17663098 — intervention group
Group type: COMPARATOR
Intervention: Simple body therapy and performance therapy
Number of subjects: 80
Study 16566082 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Number of subjects: 995
Study 16566082 — intervention group
Group type: COMPARATOR
Intervention: Non-enfuvirtide
Number of subjects: 995
Study 12147961 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE) guided cardioversion
Number of subjects: 0
Study 12147961 — intervention group
Group type: COMPARATOR
Intervention: Traditional practice of prolonged anticoagulation prior to cardioversion
Number of subjects: 0
Study 10409573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) treatment at doses of 0.5 mg and 1.5 mg administered twice daily for 4.5 days
Number of subjects: 0
Study 10409573 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise bout at maximal O(2) consumption
Number of subjects: 0
Study 7749447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandbag applied to the femoral site
Number of subjects: 300
Study 7749447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheet over the affected leg and tucked under the mattress
Number of subjects: 300
Study 7749447 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instruction to keep the leg straight and still
Number of subjects: 300
Study 2134529 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 55
Study 2134529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 6994477 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 15
Study 6994477 — intervention group
Group type: COMPARATOR
Intervention: Narcotic medications
Number of subjects: 15
Study 31643039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 2.5 mg
Number of subjects: 66
Study 31643039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg
Number of subjects: 66
Study 31643039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 7.5 mg
Number of subjects: 66
Study 31643039 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg
Number of subjects: 66
Study 31643039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg and 7.5 mg (CYP2C19 intermediate metabolizers)
Number of subjects: 66
Study 30895320 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated omega-9 (MUFA n-9) diet
Number of subjects: 200
Study 30895320 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated omega-3 (PUFA n-3) diet
Number of subjects: 200
Study 30895320 — intervention group
Group type: COMPARATOR
Intervention: Control diet (SFA)
Number of subjects: 200
Study 28851504 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus-eluting stents
Number of subjects: 1334
Study 28851504 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stents
Number of subjects: 1334
Study 25812823 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg daily for 7 days)
Number of subjects: 88
Study 25812823 — intervention group
Group type: COMPARATOR
Intervention: Control group (prostate biopsy only)
Number of subjects: 88
Study 23602132 — intervention group
Group type: EXPERIMENTAL
Intervention: SWS suppression
Number of subjects: 16
Study 23602132 — intervention group
Group type: EXPERIMENTAL
Intervention: REM-sleep disturbance
Number of subjects: 16
Study 23602132 — intervention group
Group type: COMPARATOR
Intervention: Regular sleep
Number of subjects: 16
Study 21719902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum ingestion of water (W)
Number of subjects: 12
Study 21719902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum ingestion of a commercial 8% carbohydrate-electrolyte sports beverage (CSB)
Number of subjects: 12
Study 21719902 — intervention group
Group type: COMPARATOR
Intervention: No fluid ingestion allowed (NF)
Number of subjects: 12
Study 19944359 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC I/H
Number of subjects: 1050
Study 19944359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1050
Study 19944359 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MLHFQ score
Number of subjects: 1050
Study 19944359 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in MLHFQ score at 3 months
Number of subjects: 1050
Study 19944359 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in MLHFQ score at 6 months
Number of subjects: 1050
Study 17720079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of triamcinolone acetonide (4 mg/0.1 mL)
Number of subjects: 40
Study 17720079 — intervention group
Group type: COMPARATOR
Intervention: Oral steroids (steroid group)
Number of subjects: 40
Study 17720079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of triamcinolone acetonide
Number of subjects: 40
Study 15155466 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) monotherapy (serum concentrations 346‐693 microM [50‐100 microg/mL])
Number of subjects: 18
Study 15155466 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) + all-trans retinoic acid (ATRA) (80 mg/m(2)/d, days 1‐7, every other week)
Number of subjects: 18
Study 11559644 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 or 40 mg daily)
Number of subjects: 298
Study 11559644 — intervention group
Group type: COMPARATOR
Intervention: Open antireflux surgery (ARS)
Number of subjects: 298
Study 11559644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Omeprazole and ARS)
Number of subjects: 298
Study 9040553 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber diets (fruits and vegetables)
Number of subjects: 0
Study 9040553 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber diets (citrus fiber)
Number of subjects: 0
Study 9040553 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber diets (barley fiber at high protein intake)
Number of subjects: 0
Study 9040553 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber diets (barley fiber at low protein intake)
Number of subjects: 0
Study 9040553 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber diets (coarse whole meal rye bread)
Number of subjects: 0
Study 9040553 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber diets (fine whole meal rye bread)
Number of subjects: 0
Study 7956638 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic group (n=80)
Number of subjects: 161
Study 7956638 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic group (n=81)
Number of subjects: 161
Study 7956638 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 161
Study 3312553 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (low doses)
Number of subjects: 111
Study 3312553 — intervention group
Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 111
Study 31444663 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron therapy ± red blood cell transfusion
Number of subjects: 10
Study 31444663 — intervention group
Group type: EXPERIMENTAL
Intervention: IDAT cases
Number of subjects: 10
Study 31444663 — intervention group
Group type: COMPARATOR
Intervention: ITP controls
Number of subjects: 10
Study 26582873 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR-RIT-1 (4.8 log10 CCID50)
Number of subjects: 1220
Study 26582873 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR-RIT-2 (4.1 log10 CCID50)
Number of subjects: 1220
Study 26582873 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR-RIT-3 (3.7 log10 CCID50)
Number of subjects: 1220
Study 26582873 — intervention group
Group type: COMPARATOR
Intervention: MMRII co-administered with HAV, VAR, and PCV7
Number of subjects: 1220
Study 26582873 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (MMR-RIT lots and MMRII)
Number of subjects: 1220
Study 24157526 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exercise
Number of subjects: 21
Study 24157526 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive movement
Number of subjects: 21
Study 24157526 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy)
Number of subjects: 21
Study 21593108 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial mass and ATP synthesis in myotubes from PCOS subjects
Number of subjects: 16
Study 21593108 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy weight- and age-matched)
Number of subjects: 16
Study 19339045 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycap (low doses of thiazide 12.5 mg, atenolol 50 mg, ramipril 5 mg, simvastatin 20 mg, and aspirin 100 mg per day)
Number of subjects: 2053
Study 19339045 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycap
Number of subjects: 2053
Study 19339045 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycap and other groups using atenolol
Number of subjects: 2053
Study 16987908 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-beta 36,000 IU
Number of subjects: 86
Study 16987908 — intervention group
Group type: COMPARATOR
Intervention: Epoetin-beta 9000 IU
Number of subjects: 86
Study 16987908 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-beta (all dosage groups)
Number of subjects: 86
Study 12810937 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg daily
Number of subjects: 722
Study 12810937 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg daily
Number of subjects: 722
Study 12810937 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg slow release twice daily
Number of subjects: 722
Study 10671912 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (clinical pharmacist visit and best practice chart)
Number of subjects: 112
Study 10671912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visit, no chart)
Number of subjects: 112
Study 10671912 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 112
Study 10671912 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 10671912 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study 9020593 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 9020593 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 30
Study 1532072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 100
Study 1532072 — intervention group
Group type: COMPARATOR
Intervention: Control (no fibrin glue)
Number of subjects: 100
Study 6540047 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 kcal soy protein
Number of subjects: 30
Study 6540047 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 kcal collagen protein
Number of subjects: 30
Study 6540047 — intervention group
Group type: COMPARATOR
Intervention: Total fasting with potassium
Number of subjects: 30
Study 6540047 — intervention group
Group type: COMPARATOR
Intervention: Total fasting without potassium
Number of subjects: 30
Study 30843245 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Number of subjects: 302
Study 30843245 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 100 mg
Number of subjects: 302
Study 30843245 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 302
Study 29950182 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g single dose, administered 1 day before surgery)
Number of subjects: 60
Study 29950182 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose, administered 1 day before surgery)
Number of subjects: 60
Study 29950182 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 60
Study 29950182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25582793 — intervention group
Group type: EXPERIMENTAL
Intervention: M. tuberculosis bacteremia
Number of subjects: 90
Study 24163988 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer containing licochalcone A (LicA)
Number of subjects: 55
Study 24163988 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone
Number of subjects: 55
Study 22155918 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV RNA >5 log(10) copies/ml
Number of subjects: 274
Study 19109315 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments for non-specific low back pain
Number of subjects: 76
Study 19109315 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatments with large effects (>20 points)
Number of subjects: 76
Study 17890232 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart twice daily
Number of subjects: 708
Study 17890232 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial insulin aspart three times daily
Number of subjects: 708
Study 17890232 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin detemir once daily (twice if required)
Number of subjects: 708
Study 15530130 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide 16mg with Saquinavir 600mg
Number of subjects: 12
Study 15530130 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir 600mg
Number of subjects: 12
Study 15530130 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide 16mg
Number of subjects: 12
Study 11682378 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.7%‐1.8%)
Number of subjects: 16
Study 11682378 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (105 g x kg(‐1) x min(‐1)) and Nitroglycerin (1‐6 mg/h)
Number of subjects: 16
Study 7938293 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic median nerve decompression (two-portal Chow technique)
Number of subjects: 40
Study 7938293 — intervention group
Group type: COMPARATOR
Intervention: Open median nerve decompression (Taleisnik technique)
Number of subjects: 40
Study 3365858 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 5
Study 3365858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 29395965 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg emedastine patch
Number of subjects: 1276
Study 29395965 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg emedastine patch
Number of subjects: 1276
Study 29395965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1276
Study 29395965 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg tablet)
Number of subjects: 1276
Study 26343421 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Next
Number of subjects: 30
Study 26343421 — intervention group
Group type: COMPARATOR
Intervention: ProTaper Universal (PTU)
Number of subjects: 30
Study 26343421 — intervention group
Group type: EXPERIMENTAL
Intervention: Both instruments
Number of subjects: 30
Study 25372846 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone or aripiprazole (12 weeks treatment)
Number of subjects: 24
Study 25372846 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 24
Study 23159393 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal endoscopic microsurgery (TEMS)
Number of subjects: 60
Study 23159393 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic lower anterior resection (LAR)
Number of subjects: 60
Study 21575026 — intervention group
Group type: EXPERIMENTAL
Intervention: Oct‐LAR
Number of subjects: 22
Study 21575026 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 22
Study 18291251 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal hernia repair (TEP)
Number of subjects: 168
Study 18291251 — intervention group
Group type: COMPARATOR
Intervention: Open tension-free repair (Lichtenstein repair)
Number of subjects: 168
Study 16219797 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus cyclophosphamide (FC)
Number of subjects: 375
Study 16219797 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine alone
Number of subjects: 375
Study 14623504 — intervention group
Group type: EXPERIMENTAL
Intervention: CQI group with peer review topics including 'airway aspiration' and 'measuring blood pressure'
Number of subjects: 255
Study 14623504 — intervention group
Group type: COMPARATOR
Intervention: Control group with peer review topics including 'perineal repair' and 'artificial rupture of the membranes (ARM)'
Number of subjects: 255
Study 14623504 — intervention group
Group type: EXPERIMENTAL
Intervention: CQI group with peer review topics including 'perineal repair'
Number of subjects: 255
Study 10890457 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 13
Study 10890457 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 13
Study 9312922 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFA) 5.2 g daily for 12 weeks
Number of subjects: 55
Study 9312922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9312922 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFA)
Number of subjects: 55
Study 8513986 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide with methysergide
Number of subjects: 6
Study 8513986 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide with metergoline or pizotifen
Number of subjects: 6
Study 8513986 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide with fluoxetine
Number of subjects: 6
Study 8513986 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide alone
Number of subjects: 6
Study 2880066 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 500 mg, three times a day for 10 days
Number of subjects: 40
Study 2880066 — intervention group
Group type: COMPARATOR
Intervention: Intravenous azlocillin 5 g and gentamicin 80 mg, three times a day for 10 days
Number of subjects: 40
Study 2880066 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 2880066 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 40
Study 31628272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing Scale (PCS) scores at 6 months post-ACLR
Number of subjects: 48
Study 31628272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing Scale (PCS) scores at various time points
Number of subjects: 48
Study 31628272 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative PCS scores
Number of subjects: 48
Study 28368955 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + PRO
Number of subjects: 21
Study 28368955 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 21
Study 27237081 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and support (TS)
Number of subjects: 120
Study 27237081 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial reimbursement (FR)
Number of subjects: 120
Study 27237081 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and support (TS) plus Financial reimbursement (FR)
Number of subjects: 120
Study 27237081 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and support (TS) plus Financial reimbursement (FR) plus eBI
Number of subjects: 120
Study 27237081 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 120